Insider buying last 90 days
No open-market insider purchases were filed for GRAL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
GRAIL's week centers on the FDA Advisory Committee's favorable vote on the Galleri multi-cancer early detection test, along with Q3 2026 results showing Galleri revenue up 14% year-over-year to $37.3 million and quarterly test volume up roughly 24% to more than 56,000. On the earnings call, GRAL also addressed plans to cut Galleri prices to encourage adoption ahead of an expected U.S. regulatory decision in early 2027, with the company noting 4% overall revenue growth as higher volumes were partly offset by lower pricing. The last earnings reaction, on 4 November, was -14.6% even as EPS of -2.21 beat the -2.45 estimate.
Shares closed at $128.08, up 5.5% on the day, sitting above both the 50-day average of $117.51 and the 200-day average of $78.88, with the shorter average above the longer one. The GekkoIndex reads 60.2, placing GRAL in the Accumulation zone, up 4.3 over five days. Price sits 4.1% above Gekko Fair Value of $122.98.
Over the next 20 trading days, the next earnings date falls on 18 February 2027, outside that window. Options activity shows 1 unusual signal in the last 30 days, with call premium of $406,790 and no put premium recorded. Analyst coverage includes 6 buy and 4 hold ratings among 10 firms, with a consensus target of $132.56. No seasonality read is available.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
GRAIL scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
Averages disagree
Close $115.89 sits between the 50-day ($120.87) and 200-day ($79.21) averages, or the averages disagree.
See the chart62.3, Accumulation
Reading 62.3 is in the Accumulation zone.
See the GekkoIndex9.7% below
Price is 9.7% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 95 days
Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
GRAIL closed at $115.89 on Nov 13, 2026, +39.0% over the past year, inside a 52-week range of $41.50 to $166.48.
Use the left and right arrow keys to read daily values.
Put GRAL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
GRAIL focuses on detecting cancer at an early stage through testing built around DNA methylation analysis. Its best-known offering, Galleri, is a screening test aimed at people over 50 who show no symptoms, designed to flag possible cancer before other signs appear. The company also offers a diagnostic aid meant to speed up the path to a confirmed diagnosis for patients whose doctors already suspect cancer is present.
Beyond its screening products, GRAIL supports clinical studies, pilot programs, and broader research and therapy development work for other parties. It also maintains a research-use-only methylation platform used in precision oncology, which can help gauge disease outlook, stratify patient risk, detect minimal residual disease, and monitor for recurrence or relapse. Together these offerings serve clinicians, researchers, and organizations working on cancer detection and treatment, in addition to individual patients.
GRAIL was incorporated in 2015 and operates out of Menlo Park, California, serving patients and partners both within the United States and abroad. Its shares are listed on the NASDAQ under the ticker GRAL.
GRAIL’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.3, in the Accumulation zone, up 0.6 points over five sessions.
Up 0.6 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 8 | Too few readings yet | |||
| Accumulation (current zone) | 163 | +3.2% | +16.8% | ||
| Neutral | 368 | +2.2% | +10.2% | ||
| Distribution | 49 | +3.9% | +15.1% | ||
| Selling | 10 | +14.9% | +9.8% | ||
Average GRAL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
GRAIL trades 9.7% below Gekko Fair Value of $128.30, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what GRAIL shares are worth, recalculated every trading day.
$128.30
Gekko Fair Value, Nov 14, 2026
9.7% Undervalued
At the end of Aug 2026 the price was 10.3% above the estimate.
No open-market insider purchases were filed for GRAIL, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for GRAL in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in GRAL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
GRAIL has been buying back its own shares.
From company filings.
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Nov 5, $407K in unusual premium.
0of the funds Gekko tracks hold GRAL.
GRAIL reports on Feb 18, 2027, after the close (95 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 18, 2027
Expected after the close, 95 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | −$2.21 est −$2.45 | $37.54M est $44.21M | −14.6% |
| Aug 5, 2026 | −$2.56 est −$2.91 | $44.69M est $42.39M | −12.8% |
| May 5, 2026 | −$1.37 est −$1.96 | $40.79M est $39.16M | +12.7% |
| Feb 19, 2026 | −$2.44 est −$3.33 | $43.60M est $43.58M | −50.9% |
| Nov 12, 2025 | −$2.46 est −$3.36 | $36.19M est $34.60M | −0.2% |
| Aug 12, 2025 | −$3.18 est −$3.14 | $35.54M est $34.10M | +3.9% |
| May 13, 2025 | −$3.10 est −$4.03 | $31.84M est $35.20M | −8.6% |
| Feb 20, 2025 | −$2.89 est −$4.97 | $38.25M est $35.80M | −22.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for GRAIL is $139.44, +20.3% from the last close, from 10 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 10 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Piper Sandler | $130 | +12.2% |
| Nov 9 | Guggenheim | $155 | +33.7% |
| Nov 6 | Mizuho Securities | $110 | −5.1% |
| Nov 5 | Canaccord Genuity | $150 | +29.4% |
| Nov 5 | Piper Sandler | $74 | −36.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
GRAIL’s market cap is $5.21B and revenue of $166.6M over the last twelve months.
2 headlines about GRAIL from the past week, newest first, each linking to the publisher.
GRAIL’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
GRAIL’s market cap is $5.21B at the Nov 13, 2026 close of $115.89, with 44.96M shares outstanding.
The consensus analyst 12-month price target for GRAIL is $139.44, +20.3% from the last close. Of the 10 firms that rated the stock in the last 90 days, 5 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate GRAIL is undervalued: the Nov 13, 2026 close of $115.89 is 9.7% below Gekko Fair Value of $128.30. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
GRAIL is expected to report on Feb 18, 2027, after the market closes (95 days away). Analysts expect earnings of −$2.38 per share on revenue of $45.58M. GRAIL beat the earnings estimate in 7 of its last 8 reports, moving 15.8% on average across the report.
GRAIL’s 52-week high is $166.48 and its 52-week low is $41.50; it closed at $115.89 on Nov 13, 2026, +39.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in GRAIL over the last 30 days, with $407K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 5, 2026 with $407K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.